SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Acadia Pharmaceuticals Inc. 10-K 12/31/23 88:14M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.81M 3: EX-10.13 Material Contract HTML 40K 4: EX-10.17 Material Contract HTML 610K 5: EX-10.18 Material Contract HTML 32K 6: EX-10.19 Material Contract HTML 31K 7: EX-10.20 Material Contract HTML 44K 8: EX-10.35 Material Contract HTML 355K 9: EX-10.36 Material Contract HTML 289K 10: EX-10.37 Material Contract HTML 63K 11: EX-10.38 Material Contract HTML 366K 2: EX-10.5 Material Contract HTML 97K 12: EX-21.1 Subsidiaries List HTML 26K 13: EX-23.1 Consent of Expert or Counsel HTML 28K 18: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 39K Awarded Compensation 14: EX-31.1 Certification -- §302 - SOA'02 HTML 30K 15: EX-31.2 Certification -- §302 - SOA'02 HTML 30K 16: EX-32.1 Certification -- §906 - SOA'02 HTML 27K 17: EX-32.2 Certification -- §906 - SOA'02 HTML 27K 20: R1 Document and Entity Information HTML 99K 21: R2 Consolidated Balance Sheets HTML 126K 22: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K 23: R4 Consolidated Statements of Operations HTML 94K 24: R5 Consolidated Statements of Comprehensive Loss HTML 48K 25: R6 Consolidated Statements of Cash Flows HTML 120K 26: R7 Consolidated Statements of Stockholders' Equity HTML 77K 27: R8 Pay vs Performance Disclosure HTML 38K 28: R9 Insider Trading Arrangements HTML 46K 29: R10 Organization and Business HTML 29K 30: R11 Summary of Significant Accounting Policies HTML 185K 31: R12 Investments HTML 151K 32: R13 Fair Value Measurements HTML 132K 33: R14 Balance Sheet Details HTML 91K 34: R15 Stockholders' Equity HTML 124K 35: R16 401(k) Plan HTML 33K 36: R17 Income Taxes HTML 199K 37: R18 Commitments and Contingencies HTML 64K 38: R19 Leases HTML 92K 39: R20 Selected Quarterly Financial Data (Unaudited) HTML 89K 40: R21 SCHEDULE II - Valuation and Qualifying Accounts HTML 54K 41: R22 Summary of Significant Accounting Policies HTML 239K (Policies) 42: R23 Summary of Significant Accounting Policies HTML 131K (Tables) 43: R24 Investments (Tables) HTML 148K 44: R25 Fair Value Measurements (Tables) HTML 130K 45: R26 Balance Sheet Details (Tables) HTML 93K 46: R27 Stockholders' Equity (Tables) HTML 81K 47: R28 Income Taxes (Tables) HTML 193K 48: R29 Leases (Tables) HTML 84K 49: R30 Selected Quarterly Financial Data (Unaudited) HTML 88K (Tables) 50: R31 Summary of Significant Accounting Policies - HTML 35K Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) 51: R32 Summary of Significant Accounting Policies - HTML 76K Additional Information (Detail) 52: R33 Summary of Significant Accounting Policies - HTML 36K Schedule of Estimated Useful Lives by Major Asset Category (Detail) 53: R34 Summary of Significant Accounting Policies - HTML 37K Schedule of Revenues consist of product sales to customers (Details) 54: R35 Summary of Significant Accounting Policies - HTML 36K Weighted-Average Assumptions Used to Estimate Fair Value of Employee Stock Options (Detail) 55: R36 Summary of Significant Accounting Policies - HTML 44K Weighted-Average Assumptions Used to Estimate Fair Value of Employee Stock Purchase Plan Rights (Detail) 56: R37 Summary of Significant Accounting Policies - HTML 35K Summary of Stock-based Compensation Expense Included in Statements of Operations (Detail) 57: R38 Investments - Carrying Value and Amortized Cost of HTML 58K Company's Investments Summarized by Major Security Type (Detail) 58: R39 Investments - Additional Information (Detail) HTML 35K 59: R40 Investments - Summary of Gross Unrealized Losses HTML 53K and Fair Value of Available-For-Sale Investment Securities in Unrealized Loss Position (Detail) 60: R41 Fair Value Measurements - Fair Value Measurements HTML 62K of Cash Equivalents, Available-For-Sale Investment Securities and Equity Securities (Detail) 61: R42 Fair value measurement - Changes in estimated fair HTML 34K value of contingent cash award (Details) 62: R43 Balance Sheet Details - Schedule of Inventory HTML 38K (Detail) 63: R44 Balance Sheet Details - Property and Equipment, HTML 40K Net (Detail) 64: R45 Balance Sheet Details - Additional Information HTML 29K (Detail) 65: R46 Balance Sheet Details - Schedule of Accrued HTML 42K Liabilities (Detail) 66: R47 Stockholders' Equity - Additional Information HTML 141K (Detail) 67: R48 Summary of Company's Stock Option Activity HTML 68K (Detail) 68: R49 Summary of Company's RSU Activity (Detail) HTML 51K 69: R50 401 (k) Plan - Additional Information (Detail) HTML 33K 70: R51 Income Taxes - Summary of Domestic and Foreign HTML 34K Pre-tax Loss (Detail) 71: R52 Income Taxes - Schedule of Income Tax Provision HTML 40K (Details) 72: R53 Income Taxes - Additional Information (Detail) HTML 62K 73: R54 Income Taxes - Components of Deferred Tax Assets HTML 61K (Detail) 74: R55 Income Taxes - Reconciliation of Income Taxes to HTML 60K Amount Computed by Applying Statutory Federal Income Tax Rate to Pretax Loss (Detail) 75: R56 Income Taxes - Unrecognized Tax Benefits (Detail) HTML 34K 76: R57 Commitments and Contingencies - Additional HTML 95K Information (Detail) 77: R58 Leases - Additional Information (Detail) HTML 88K 78: R59 Leases - Summary of Operating Lease Costs (Detail) HTML 31K 79: R60 Leases - Supplemental Cash Flow Information HTML 29K Related to the Company's Leases (Detail) 80: R61 Leases - Summary of Balance Sheet Classification HTML 33K of Lease Liabilities (Detail) 81: R62 Leases - Summary of Maturities of Lease HTML 46K Liabilities (Detail) 82: R63 Selected Quarterly Financial Data (Unaudited) - HTML 72K Selected Quarterly Financial Data (Detail) 83: R64 SCHEDULE II - Valuation and Qualifying Accounts HTML 37K (Detail) 85: XML IDEA XML File -- Filing Summary XML 147K 88: XML XBRL Instance -- acad-20231231_htm XML 2.93M 84: EXCEL IDEA Workbook of Financial Report Info XLSX 167K 19: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 3.61M Linkbases Document -- acad-20231231 86: JSON XBRL Instance as JSON Data -- MetaLinks 566± 903K 87: ZIP XBRL Zipped Folder -- 0000950170-24-021473-xbrl Zip 988K
EX-32.2 |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Acadia Pharmaceuticals Inc. (the “Company”) on Form 10-K for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Mark C. Schneyer, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Report and results of operations of the Company for the period covered by the Report.
Date: February 27, 2024 |
/s/ MARK C. SCHNEYER |
|
Mark C. Schneyer Executive Vice President, Chief Financial Officer (Registrant’s Principal Financial Officer) |
This certification shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of Section 18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed as of: | 2/28/24 | |||
Filed on: | 2/27/24 | 4, 8-K | ||
For Period end: | 12/31/23 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/09/24 Acadia Pharmaceuticals Inc. 10-Q 3/31/24 62:7.2M Donnelley … Solutions/FA |